Please provide your email address to receive an email when new articles are posted on . Adults either continued to receive ublituximab or switched from teriflunomide to ublituximab in this 3-year open ...

Please provide your email address to receive an email when new articles are posted on . The most common comorbidity for both subsets of the study population was obesity. Risk for infection-related ...

TG Therapeutics secured $500 million in non-dilutive capital through a new credit facility, supporting the expansion of ...

--TG Therapeutics, Inc., today announced updated data presentations including new six-year data from the ULTIMATE I& II Phase 3 trials evaluating BRIUMVI ® in patients with relapsing forms of multiple ...

- FENhance 1 met its primary endpoint, showing investigational fenebrutinib significantly reduced relapses by 51% compared to teriflunomide in relapsing multiple sclerosis (RMS), consistent with ...

FENhance 1 met its primary endpoint, showing investigational fenebrutinib significantly reduced relapses by 51% compared to teriflunomide in relapsing multiple sclerosis (RMS), consistent with ...

Key updates in disease-modifying therapies for relapsing-remitting multiple sclerosis (RRMS) from the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) forum are reported ...

Ublituximab reduces relapse rates and disability progression over 5 years in patients with relapsing multiple sclerosis.

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the pivotal Phase III study (FENhance 1) of fenebrutinib in RMS met its primary endpoint, showing clinically ...